Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Spero Therapeutics, Inc. (SPRO : NSDQ)

• Company Description    Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. Number of Employees: 32

• Price / Volume Information    Yesterday's Closing Price: $2.32 Daily Weekly Monthly 20 Day Moving Average: 328,851 shares Shares Outstanding: 56.34 (millions) Market Capitalization: $130.71 (millions) Beta: 1.48 52 Week High: $3.22 52 Week Low: $0.51 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.92% -6.17% 12 Week 16.00% 12.68% Year To Date 125.24% 94.45%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 675 Massachusetts Avenue 14th Floor - Cambridge,MA 02139 USA ph: 857-242-1600 fax: - ir@sperotherapeutics.com https://sperotherapeutics.com

• General Corporate Information    Officers Esther Rajavelu - Chief Executive Officer; Chief Financial Officer; Milind Deshpande - Director Scott Jackson - Director Cynthia Smith - Director Kathleen Tregoning - Director Peer Information Spero Therapeutics, Inc. (CORR.) Spero Therapeutics, Inc. (RSPI) Spero Therapeutics, Inc. (CGXP) Spero Therapeutics, Inc. (BGEN) Spero Therapeutics, Inc. (GTBP) Spero Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 84833T103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/26/26 Share - Related Items Shares Outstanding: 56.34 Most Recent Split Date: (:1) Beta: 1.48 Market Capitalization: $130.71 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.65 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.93 Price/Cash Flow: - Price / Sales: 3.22 EPS Growth vs. Year Ago Period: 59.38% vs. Previous Quarter: -333.33% Sales Growth vs. Year Ago Period: -59.60% vs. Previous Quarter: -61.65% ROE 09/30/25 - -125.91 06/30/25 - -120.27 03/31/25 - -123.50 ROA 09/30/25 - -57.58 06/30/25 - -55.61 03/31/25 - -58.96 Current Ratio 09/30/25 - 3.83 06/30/25 - 3.97 03/31/25 - 2.56 Quick Ratio 09/30/25 - 3.83 06/30/25 - 3.97 03/31/25 - 2.56 Operating Margin 09/30/25 - -108.11 06/30/25 - -110.35 03/31/25 - -156.48 Net Margin 09/30/25 - -108.11 06/30/25 - -110.35 03/31/25 - -156.48 Pre-Tax Margin 09/30/25 - -107.39 06/30/25 - -110.35 03/31/25 - -156.48 Book Value 09/30/25 - 0.47 06/30/25 - 0.59 03/31/25 - 0.60 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©